Potassium Phosphate Injection Composition With Controlled Osmolality

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current potassium phosphate injections require dilution before use, leading to potential contamination, dosing errors, and aluminum toxicity risks, with osmolality issues causing phlebitis, and lack stability at room temperature.

Innovation Solution

A ready-to-use potassium phosphate injection composition comprising monobasic and dibasic potassium phosphate with a tonicity agent, maintaining osmolality between 250-450 mOsmol/kg, and aluminum content ≤25 mcg/mL, stable for up to 6 months at various temperatures, eliminating the need for dilution and reducing contamination risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If concentrated potassium phosphate solution is used, then storage stability is improved, but aluminum toxicity risk increases and phlebitis risk increases due to high osmolality

Engineering Contradiction:
Improvestorage stabilityVSAvoidaluminum toxicity risk
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameters of potassium phosphate (providing 3 mmol/mL phosphorus and 4.4 mEq/mL potassium in concentrated form) while controlling aluminum content through formulation and manufacturing processes. The concentrated solution maintains stability while aluminum levels are managed to meet FDA limits of 25 mcg/L in LVP products.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent segments the solution into concentrated stock solution and diluent components, allowing the concentrated potassium phosphate to be stored stably while the final diluted administration solution achieves safe aluminum levels and appropriate osmolality for peripheral vein infusion.

Inventive Principle:
Principle #1Segmentation

2Stability of the object's composition

If concentrated potassium phosphate solution is used, then storage stability is improved, but phlebitis risk increases due to high osmolality

Engineering Contradiction:
Improvestorage stabilityVSAvoidphlebitis risk
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent provides concentrated potassium phosphate solution with controlled osmolality parameters that can be adjusted through dilution. The concentrated form maintains stability, while the final diluted solution achieves osmolality suitable for peripheral vein administration, reducing phlebitis risk.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent segments the administration process into concentrated storage solution and diluent components, enabling the stable concentrated form to be stored long-term while the diluted administration solution achieves appropriate osmolality for safe peripheral vein infusion.

Inventive Principle:
Principle #1Segmentation

3Object-affected harmful factors

If dilution is required before administration, then osmolality is reduced to safe levels, but contamination risk and dosing errors increase

Engineering Contradiction:
Improveosmolality controlVSAvoidcontamination risk
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent provides pre-prepared concentrated potassium phosphate solution with controlled composition and sterility, eliminating the need for clinical dilution operations that could introduce contamination or dosing errors. The solution is ready for direct use or controlled dilution with reduced error risk.

Inventive Principle:
Principle #10Preliminary action

4Object-affected harmful factors

If dilution is required before administration, then osmolality is reduced to safe levels, but dosing errors increase

Engineering Contradiction:
Improveosmolality controlVSAvoiddosing accuracy
Core Design Contradiction:
Object-affected harmful factorsVSManufacturing precision

Solution Approach 1:

The patent provides pre-formulated concentrated solution with precisely controlled potassium (4.4 mEq/mL) and phosphorus (3 mmol/mL) concentrations, eliminating dilution-related dosing errors. The concentrated form allows accurate dosing through simple volume calculations while maintaining flexibility for osmolality adjustment through controlled dilution.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS20260007695A1Ready-to-use potassium phosphate injection
Publication Date: 2026.01.08 AMNEAL EU LTD

AI summary

The present invention relates to a ready-to-use injection compositions of potassium phosphates water for injection and a tonicity agent and methods for preparing the same. The ready-to-use injection compositions contain 15 mmol/250 mL of phosphorus, 22 mEq/250 mL of potassium, equal or less than about 25 mcg/mL of aluminum and exhibit an osmolality value of from about 250 mOsmol/kg to about 450 mOsmol/kg. The ready-to-use injection compositions of the disclosure do not require any further reconstitution step prior to use.